The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-21. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Braden Eric Peters (born 2005 or 2006), better known as Clavicular or Clav, is an American livestreamer, internet personality, and influencer. He rose to popularity on social media in 2025–2026 for promoting "looksmaxxing", a trend of using extreme methods to improve one's appearance, such as "bonesmashing", a pseudoscientific practice involving hitting one's facial bones with a hammer or fist, as well as the use of anabolic steroids and methamphetamine as an appetite suppressant. On September 8, 2026, charges were filed against Peters in Massachusetts state court for criminal rape, drugging, and providing alcohol to a minor.
The acidity of lactic acid impedes biological processes. This can be beneficial to the fermenting organism as it drives out competitors that are unadapted to the acidity. As a result, the food will have a longer shelf life (one reason foods are purposely fermented in the first place); however, beyond a certain point, the acidity starts affecting the organism that produces it. The high concentration of lactic acid (the final product of fermentation) drives the equilibrium backwards (Le Chatelier's principle), decreasing the rate at which fermentation can occur and slowing down growth. Ethanol, into which lactic acid can be easily converted, is volatile and will readily escape, allowing the reaction to proceed easily. CO2 is also produced, but it is only weakly acidic and even more volatile than ethanol. Acetic acid (another conversion product) is acidic and not as volatile as ethanol; however, in the presence of limited oxygen, its creation from lactic acid releases additional energy. It is a lighter molecule than lactic acid, forming fewer hydrogen bonds with its surroundings (due to having fewer groups that can form such bonds), thus is more volatile and will also allow the reaction to proceed more quickly. If propionic acid, butyric acid, and longer monocarboxylic acids are produced, the amount of acidity produced per glucose consumed will decrease, as with ethanol, allowing faster growth.
== History == The first recorded observation of capillary action was by Leonardo da Vinci. A former student of Galileo, Niccolò Aggiunti, was said to have investigated capillary action. In 1660, capillary action was still a novelty to the Irish chemist Robert Boyle, when he reported that "some inquisitive French Men" had observed that when a capillary tube was dipped into water, the water would ascend to "some height in the Pipe". Boyle then reported an experiment in which he dipped a capillary tube into red wine and then subjected the tube to a partial vacuum. He found that the vacuum had no observable influence on the height of the liquid in the capillary, so the behavior of liquids in capillary tubes was due to some phenomenon different from that which governed mercury barometers. Others soon followed Boyle's lead. Some (e.g., Honoré Fabri, Jacob Bernoulli) thought that liquids rose in capillaries because air could not enter capillaries as easily as liquids, so the air pressure was lower inside capillaries. Others (e.g., Isaac Vossius, Giovanni Alfonso Borelli, Louis Carré, Francis Hauksbee, Josia Weitbrecht) thought that the particles of liquid were attracted to each other and to the walls of the capillary. Although experimental studies continued during the 18th century, a successful quantitative treatment of capillary action was not attained until 1805 by two investigators: Thomas Young of the United Kingdom and Pierre-Simon Laplace of France. They derived the Young–Laplace equation of capillary action.
Sources: en.wikipedia.org
Apoptosis. During programmed cell death the ICE/ced-3 family of proteases (one of the interleukin-1β-converter proteases) degrade actin into two fragments in vivo; one of the fragments is 15 kDa and the other 31 kDa. This represents one of the mechanisms involved in destroying cell viability that form the basis of apoptosis. The protease calpain has also been shown to be involved in this type of cell destruction; just as the use of calpain inhibitors has been shown to decrease actin proteolysis and the degradation of DNA (another of the characteristic elements of apoptosis). On the other hand, the stress-induced triggering of apoptosis causes the reorganization of the actin cytoskeleton (which also involves its polymerization), giving rise to structures called stress fibers; this is activated by the MAP kinase pathway.
The United States war on drugs in Latin America began with the Nixon Administration. This led to large amounts of US funding and manpower being dedicated to help stop the Latin American production of drugs and slow the flow of drugs coming into the United States from Latin America. One major milestone in the efforts for both Latin American countries and the United States was the signing of extradition treaties for drug traffickers. This has led to notable traffickers and kingpins like El Chapo (Joaquín Archivaldo Guzmán Loera) being imprisoned in the United States. Drug trafficking from Latin America has played a major role in the United States for the past 50 years. This was notably seen in Miami when cocaine production skyrocketed in the 1970s. Since 2008, the U.S. Congress has supported the Central American Regional Security Initiative (CARSI) with approximately $800 million to "fund programs for narcotics interdiction, strengthening law enforcement and justice institutions and violence prevention through work with at-risk youth". The CARSI offers equipment (vehicles and communication equipment), technical support and guidance to counter drug trade. The program also supports special units that cooperate with the U.S. Drug Enforcement Administration in Guatemala and Honduras to investigate drug cartels, share intelligence, and promote regional collaboration.
syringae bacteria can adapt genetically to infect resistant plants, and the process for resistance breeding has to start over again. A combination treatment of bacteriophage and carvacrol shows promise in control of both the planktonic and biofilm forms.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.